AU2021270940A1 - Antibody drug conjugate, preparation method therefor and use thereof - Google Patents

Antibody drug conjugate, preparation method therefor and use thereof Download PDF

Info

Publication number
AU2021270940A1
AU2021270940A1 AU2021270940A AU2021270940A AU2021270940A1 AU 2021270940 A1 AU2021270940 A1 AU 2021270940A1 AU 2021270940 A AU2021270940 A AU 2021270940A AU 2021270940 A AU2021270940 A AU 2021270940A AU 2021270940 A1 AU2021270940 A1 AU 2021270940A1
Authority
AU
Australia
Prior art keywords
antibody
cancer
seq
sequence
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021270940A
Other languages
English (en)
Inventor
Dengnian LIU
Shuai SONG
Qiang Tian
Cheng Wang
Jingyi Wang
Liang Xiao
Tongtong XUE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sichuan Kelun Biotech Biopharmaceutical Co Ltd
Original Assignee
Sichuan Kelun Biotech Biopharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sichuan Kelun Biotech Biopharmaceutical Co Ltd filed Critical Sichuan Kelun Biotech Biopharmaceutical Co Ltd
Publication of AU2021270940A1 publication Critical patent/AU2021270940A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68037—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a camptothecin [CPT] or derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6863—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from stomach or intestines cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2021270940A 2020-05-15 2021-05-12 Antibody drug conjugate, preparation method therefor and use thereof Pending AU2021270940A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202010410633.5 2020-05-15
CN202010410633 2020-05-15
PCT/CN2021/093348 WO2021228141A1 (zh) 2020-05-15 2021-05-12 抗体药物缀合物及其制备方法和用途

Publications (1)

Publication Number Publication Date
AU2021270940A1 true AU2021270940A1 (en) 2022-12-15

Family

ID=78525267

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021270940A Pending AU2021270940A1 (en) 2020-05-15 2021-05-12 Antibody drug conjugate, preparation method therefor and use thereof

Country Status (18)

Country Link
US (1) US20230338565A1 (cg-RX-API-DMAC7.html)
EP (1) EP4151235A4 (cg-RX-API-DMAC7.html)
JP (2) JP7407973B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230012000A (cg-RX-API-DMAC7.html)
CN (1) CN115715202B (cg-RX-API-DMAC7.html)
AU (1) AU2021270940A1 (cg-RX-API-DMAC7.html)
CA (1) CA3178406A1 (cg-RX-API-DMAC7.html)
CL (2) CL2022003170A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022016208A2 (cg-RX-API-DMAC7.html)
CR (1) CR20220580A (cg-RX-API-DMAC7.html)
DO (1) DOP2022000251A (cg-RX-API-DMAC7.html)
EC (1) ECSP22089507A (cg-RX-API-DMAC7.html)
GE (2) GEP20257719B (cg-RX-API-DMAC7.html)
IL (1) IL298184A (cg-RX-API-DMAC7.html)
JO (1) JOP20220306A1 (cg-RX-API-DMAC7.html)
MX (1) MX2022014332A (cg-RX-API-DMAC7.html)
PE (1) PE20230373A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021228141A1 (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022402783A1 (en) * 2021-12-02 2024-06-13 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Method for preparing drug-linker conjugate
WO2023143208A1 (zh) * 2022-01-26 2023-08-03 苏州宜联生物医药有限公司 一种药物连接体偶联物的制备方法
CN119486763A (zh) * 2022-07-14 2025-02-18 苏州宜联生物医药有限公司 抗体药物偶联物及其制备方法和用途
JP2025527263A (ja) * 2022-08-02 2025-08-20 ノナ・バイオサイエンシズ(スーチョウ)カンパニー,リミテッド Msln抗体-薬物コンジュゲート
EP4623936A1 (en) 2022-11-22 2025-10-01 Keymed Biosciences (Chengdu) Co., Ltd. Fused ring compound, conjugate thereof and use thereof
WO2024175042A1 (zh) * 2023-02-24 2024-08-29 四川科伦博泰生物医药股份有限公司 药物偶联物治疗肿瘤疾病的用途及方法
EP4673475A1 (en) * 2023-03-02 2026-01-07 Multitude Therapeutics Inc. Antibody-drug conjugates, pharmaceutical compositions and uses thereof
AU2024263367A1 (en) * 2023-04-27 2025-11-13 CSPC Megalith Biopharmaceutical Co., Ltd. Antibody-drug conjugate
WO2024222841A1 (zh) * 2023-04-27 2024-10-31 石药集团巨石生物制药有限公司 一种抗体药物偶联物
EP4461317A1 (en) * 2023-05-12 2024-11-13 Emergence Therapeutics GmbH Antibody-drug conjugates comprising an anti-nectin-4 antibody and belotecan or a derivative thereof
JP2026521546A (ja) * 2023-06-16 2026-06-30 フォートビタ バイオロジクス(シンガポール)プライベート リミティド Claudin 18.2を標的とした抗体薬物複合体による固形腫瘍の治療方法
CN117327182B (zh) * 2023-09-19 2024-06-04 上海交通大学医学院附属仁济医院 Cldn18.2单域抗体探针的制备方法及应用
AU2024380559A1 (en) 2023-11-17 2026-06-04 Mersana Therapeutics, Inc. Treatment of cancer using b7-h4-targeted antibody-drug conjugates
WO2026086855A1 (zh) * 2024-10-25 2026-04-30 石药集团巨石生物制药有限公司 一种靶向cdcp1的抗体药物偶联物及其用途
WO2026151884A1 (en) 2025-01-09 2026-07-16 Mersana Therapeutics, Inc. Treatment of cancer using b7-h4-targeted antibody-drug conjugates

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE60131456T2 (de) 2000-11-30 2008-07-10 Medarex, Inc., Milpitas Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern
EP1790664A1 (en) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
EP1997832A1 (en) 2007-05-29 2008-12-03 Ganymed Pharmaceuticals AG Monoclonal antibodies against Claudin-18 for treatment of cancer
US9056092B2 (en) 2011-12-02 2015-06-16 Ethicon, Inc. Hemostatic bioabsorbable device with polyethylene glycol binder
WO2013174404A1 (en) * 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
CN107753954A (zh) * 2012-12-13 2018-03-06 免疫医疗公司 功效改进且毒性降低的抗体与sn‑38的免疫缀合物的剂量
KR102236367B1 (ko) 2013-07-26 2021-04-05 삼성전자주식회사 DARPin을 포함하는 이중 특이 키메라 단백질
WO2015141862A1 (en) 2014-03-17 2015-09-24 Mitsubishi Tanabe Pharma Corporation Antibody-fynomer conjugates
WO2016165762A1 (en) * 2015-04-15 2016-10-20 Ganymed Pharmaceuticals Ag Drug conjugates comprising antibodies against claudin 18.2
WO2018006882A1 (zh) * 2016-07-08 2018-01-11 科济生物医药(上海)有限公司 抗密蛋白18a2的抗体及其应用
CN119219654A (zh) * 2017-12-15 2024-12-31 四川科伦博泰生物医药股份有限公司 生物活性物偶联物及其制备方法和用途
CN111447939B (zh) * 2018-01-30 2024-07-12 四川科伦博泰生物医药股份有限公司 制备偶联物的方法
CN111542324B (zh) * 2018-02-11 2023-09-12 四川科伦博泰生物医药股份有限公司 细胞毒性剂及其偶联物、其制备方法及用途
CA3087423A1 (en) * 2018-03-14 2019-09-19 Beijing Xuanyi Pharmasciences Co., Ltd. Anti-claudin 18.2 antibodies
CN111110862A (zh) * 2018-11-01 2020-05-08 上海健信生物医药科技有限公司 抗cldn18.2抗体的药物偶联体及其制备方法和用途
EP3824096A4 (en) * 2018-07-18 2022-04-20 AskGene Pharma Inc. NOVEL ANTIBODIES AND METHODS FOR THE PRODUCTION AND USE THEREOF
WO2020023679A1 (en) * 2018-07-25 2020-01-30 Accurus Biosciences, Inc. Novel cldn 18.2-specific monoclonal antibodies and methods of use thereof
KR20210109520A (ko) 2018-12-28 2021-09-06 쓰촨 케룬-바이오테크 바이오파마수티컬 컴퍼니 리미티드 항체 및 이의 용도
WO2021237717A1 (zh) * 2020-05-29 2021-12-02 武汉友芝友生物制药有限公司 抗cldn18.2和cd3的双特异性抗体

Also Published As

Publication number Publication date
IL298184A (en) 2023-01-01
CN115715202A (zh) 2023-02-24
WO2021228141A1 (zh) 2021-11-18
DOP2022000251A (es) 2023-04-16
CR20220580A (es) 2023-04-11
KR20230012000A (ko) 2023-01-25
CL2024002956A1 (es) 2025-01-24
JP2024037960A (ja) 2024-03-19
ECSP22089507A (es) 2023-02-28
EP4151235A1 (en) 2023-03-22
CA3178406A1 (en) 2021-11-18
JP7407973B2 (ja) 2024-01-04
JOP20220306A1 (ar) 2022-11-10
CO2022016208A2 (es) 2023-02-27
US20230338565A1 (en) 2023-10-26
CN115715202B (zh) 2025-11-04
JP2023525120A (ja) 2023-06-14
JP7734178B2 (ja) 2025-09-04
PE20230373A1 (es) 2023-03-06
GEAP202416114A (en) 2024-08-26
GEP20257719B (en) 2025-01-27
CL2022003170A1 (es) 2023-05-19
EP4151235A4 (en) 2025-08-06
MX2022014332A (es) 2022-12-13

Similar Documents

Publication Publication Date Title
JP7407973B2 (ja) 抗体薬物複合体、その調製方法、およびその使用
US20250340630A1 (en) Antibody and use thereof
JP7452818B2 (ja) 新規抗ccr8抗体
CN111196852A (zh) 抗tigit抗体及其用途
EP4039704A1 (en) Anti-pd-1 antibody and use thereof
US20250340631A1 (en) Cldn18.2-targeting antibody, bispecific antibody and use thereof
EP4292611A1 (en) Anti-cd112r antibody and use thereof
CN110366564B (zh) 使用与程序性死亡1(pd-1)结合的抗体的免疫疗法
EP4640707A1 (en) Anti-cmet antibody, antibody-drug conjugate, and preparation method therefor and use thereof
EP4349867A1 (en) Specific binding protein targeting pd-l1 and cd73
CN119487070A (zh) 靶向cd117的抗体
HK40090265A (en) Antibody drug conjugate, preparation method therefor and use thereof
JP2023536499A (ja) ヒトアンジオポエチン-2に対する抗体及びその使用
EA050737B1 (ru) Конъюгат антитело-лекарственное средство, способ его получения и его применение
HK40048164B (en) Antibody and use thereof
WO2025228351A1 (zh) 抗体,抗体药物偶联物及其用途
HK40048164A (en) Antibody and use thereof
AU2023404588A1 (en) Anti-cldn18.2 antibody-drug conjugate, and pharmaceutical composition thereof and use thereof
HK40066347B (en) Cldn18.2-targeting antibody, preparation method thereof, and use thereof